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Abstract
Background: Children living with HIV continue to be in urgent need of combined antiretroviral therapy (ART).
Strategies to scale up and improve pediatric HIV care in resource-poor regions, especially in sub-Saharan Africa,
require further research from these settings. We describe treatment outcomes in children treated in rural Uganda
after 1 and 2 years of ART start.
Methods: Cross-sectional assessment of all children treated with ART for 12 (M12) and 24 (M24) months was performed.
CD4 counts, HIV RNA levels, antiretroviral resistance patterns, and non-nucleoside reverse transcriptase inhibitor (NNRTI)
plasma concentrations were determined. Patient adherence and antiretroviral-related toxicity were assessed.
Results: Cohort probabilities of retention in care were 0.86 at both M12 and M24. At survey, 71 (83%, M12) and 32
(78%, M24) children remained on therapy, and 84% participated in the survey. At ART start, 39 (45%) were female;
median age was 5 years. Median initial CD4 percent was 11% [IQR 9-15] in children < 5 years old (n = 12); CD4
count was 151 cells/mm
3 [IQR 38-188] in those ≥ 5 years old (n = 26). At M12, median CD4 gains were 11% [IQR
10-14] in patients < 5 years old, and 206 cells/mm
3 [IQR 98-348] in ≥ 5 years old. At M24, median CD4 gains were
11% [IQR 5-17] and 132 cells/mm
3 [IQR 87-443], respectively. Viral suppression (< 400 copies/mL) was achieved in
59% (M12) and 33% (M24) of children. Antiretroviral resistance was found in 25% (M12) and 62% (M24) of children.
Overall, 29% of patients had subtherapeutic NNRTI plasma concentrations.
Conclusions: After one year of therapy, satisfactory survival and immunological responses were observed, but
nearly 1 in 4 children developed viral resistance and/or subtherapeutic plasma antiretroviral drug levels. Regular
weight-adjustment dosing and strategies to reinforce and maintain ART adherence are essential to maximize
duration of first-line therapy in children in resource-limited countries.
Keywords: Children, antiretroviral therapy, Uganda, rural population, patient compliance, drug resistance,
pharmacokinetics
Background
Despite the progress made in the last few years, in 2009
only 356,400 of the estimated 2.5 million children cur-
rently infected with HIV were receiving combined anti-
retroviral therapy (ART) in low- and middle-income
countries [1]. Ninety percent of children infected with
HIV were living in sub-Saharan Africa and the ART
coverage in this area was 26% [2]. In the absence of
therapy, more than 50% of HIV-infected children die
before the age of 2 years [3]. Therefore, there is an
urgent need to increase access to treatment and care
and to monitor the effectiveness of therapy.
Comprehensive evaluations of the effectiveness of gen-
eric fixed-drug ART in children come mainly from stu-
dies conducted in high-income countries [4-8] and, to a
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[9,10]. Assessments conducted in rural, resource-limited
settings, where programs face important challenges to
provide pediatric HIV care, are needed to adapt and
improve existing treatment strategies.
In this study, we evaluated pediatric care provision in
an HIV/AIDS program in rural, northwestern Uganda.
Specifically, we describe survival and program retention,
and, among children alive and on ART, patient adher-
ence to therapy and presence of antiretroviral (ARV)-
related toxicity. Also presented are plasma non-nucleo-
side reverse transcriptase inhibitor (NNRTI) concentra-
tions and CD4 and virological responses, including
resistance patterns, observed in children with detectable
HIV viral load.
Methods
Arua Hospital AIDS Care Project
T h eA r u aH o s p i t a lA I D SC a r eP r o j e c ti nA r u a ,U g a n d a
has provided free treatment and care to patients living
with HIV/AIDS since July 2002. Eligibility criteria for
ART, patient management, and treatment are based on
World Health Organization (WHO) guidelines for scal-
ing up ART in resource-poor settings [11,12].
Pediatric first-line ART doses are adapted to children’s
weight. At the time of the study, children weighing < 10
kg received pediatric syrups of zidovudine (AZT)-lamivu-
dine (3TC)-nevirapine (NVP); those 10-24 kg, adult
fixed-dose combination (FDC) Triviro (3TC-stavudine
[d4T]-NVP) or Coviro (3TC-d4T) tablets divided in half;
and those ≥ 25 kg, whole tablets of Triviro or Triomune
(3TC-d4T-NVP). In case of drug intolerance to NVP, efa-
virenz (EFV) was used. Due to drug shortages of Coviro
and Triviro, between May 2004 and May 2006 children
weighting ≥10 kg were given either whole or half Trio-
mune tablets according to body weight. Second-line ther-
apy regimens combined didanosine (ddI)-boosted
lopinavir (LPV/r) and either AZT or abacavir (ABC) [13].
Nurses or clinical officers monitored the children
every 2 to 6 months to determine clinical stage and
diagnosed and treated ARV-related toxicity or intercur-
rent diseases. CD4 testing was performed at initiation
and every 6 months thereafter (every year after 2005).
No routine viral load monitoring was performed. Adher-
ence counseling focused on parent/caregiver education.
No specialized child psychological support or specific
training for pediatric clinical management was offered at
that time.
Study Population
We retrospectively analyzed two observational cohorts
of children treated with ART for 12 ± 2 months (M12
cohort) or 24 ± 2 months (M24 cohort). Children alive
still followed on treatment were eligible to participate in
the cross-sectional survey, conducted between Novem-
ber 2005 and May 2006.
Study Procedures
We used a standardized questionnaire to collect socio-
demographic information, WHO clinical stage data,
weight, height, ART information (history of ARV use
before enrollment, date of therapy start and regimen,
current regimen), reported clinical ARV intolerances
(asthenia, lipodystrophy, or gastrointestinal, cutaneous,
and neurological symptoms), presence of ARV-related
morphological disorders, and adherence to treatment.
Two indicators of adherence as reported by parents/
caregivers were used: i) percentage of pills taken in the
last 4 days (number of pills taken divided by the total
number of pills prescribed during the previous 4 days);
and ii) percentage of adherence during the last 30 days
using a 6-point visual analogue scale (VAS; 0 meaning
no medication taken, and 6 all medication taken). For
both indicators, poor adherence was defined using a
threshold of < 95% [11], moderate adherence as 95-99%,
and good adherence as 100%.
Hemoglobin level, platelet count, neutrophil fraction,
plasma creatinine level, and transaminase level were
measured in the children. Proteinuria and glucosuria
was also determined using a urine dipstick technique.
Severity of laboratory-based ARV toxicity was graded
according to WHO guidelines [14]. CD4 counts were
measured using either semi-automated (Cyflow counter,
Partec, Münster, Germany) or manual (Dynabead, Dynal
Biotech SA, Compiègne, France) techniques. HIV RNA
testing was quantified with the automated TaqMan real-
time reverse transcription-PCR (RT-PCR) assay (limit of
detection 400 copies/mL) [15].
Samples of children with virological failure (viral load
≥ 1,000 copies/mL) were tested for genotypic resistance.
Resistance mutation determination was based on the
International AIDS Society Resistance Testing-USA
panel and resistant virus defined according to the
French ANRS resistance algorithm (http://www.hivfren-
chresistance.org) [16,17]. High performance liquid chro-
matography (HPLC) [18,19] was used to determine NVP
or EFV plasma concentrations in blood samples col-
lected 12 hours after the last dose intake.
Signed informed consent was sought from all parents
or legal caregivers. The study protocol was approved by
the Uganda National Council for Science and Technol-
ogy, the Ugandan AIDS Research Committee, and the
Saint-Germain-en-Laye Hospital Consultative Ethics
Committee, France.
Statistical Analysis
Weight-for-height nutritional Z-scores (WHZ) were calcu-
lated using WHO growth reference data for children and
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Page 2 of 9adolescents [20-22]. Normal NNRTI therapeutic ranges
(4,000-8,000 ng/mL for NVP and 1,000-4,000 ng/mL for
EFV) [23], were used to define three categories of plasma
concentrations: low (below the lower therapeutic limit),
normal (within the therapeutic range), and high (above the
higher therapeutic limit). Immunological failure was
defined according to WHO guidelines [24]: CD4 values <
15% in children of < 36 months, < 10% in the 36-59 month
group, and < 100 cells/mm
3 in those aged ≥ 5 years.
Children who missed their last appointment for 2
months or more were considered lost-to-follow-up
(LFU). Probabilities of survival and care retention were
estimated using Kaplan-Meier methods. Patient follow-
up was right-censored at the date of the study visit,
death, or last visit for children LFU or transferred to
a n o t h e rp r o g r a m .A l ls t u d yd a t aw e r ed o u b l e - e n t e r e d
and analyses performed in Stata 9.0 (Stata Corp., College
Station, TX, USA).
Results
Eighty-seven children had initiated ART 12 ± 2 months
(M12 cohort), and 41 children 24 ± 2 months (M24
cohort), before the study inclusion period (Figure 1). Over-
all, 6 children died, 11 were LFU, and 9 transferred to
another program. A total of 102 children (80% of M12 and
79% of M24) were still alive and receiving ART. Of these,
59 (M12) and 27 (M24) children, respectively, participated
in the cross-sectional survey (11 patients could not be
found and 5 were screened too late).
Of the 6 recorded deaths before the survey, 4 occurred
within 6 months of treatment start. Median time to
death was 2.3 months [IQR 1.7-7.8]. Probabilities of care
retention were 0.91 (95% CI: 0.85-0.95) at 6 months and
0.86 (95% CI: 0.79-0.91) at both 12 and 24 months.
Probabilities of survival among children not LFU were
0.97 (95% CI: 0.91-0.99) at 6 months, and 0.95 (95% CI:
0.88-0.98) at both 12 and 24 months.
Characteristics at ART Initiation
At ART initiation, 39 (45.3%) of the children surveyed
were female, median age was 5 years [IQR 3-8], and no
children were aged < 12 months (Table 1). Fifty-one
(59.3%) children were in clinical stage 3, and 14 (16.3%)
in stage 4. Eighteen of 77 (23.4%) children had WHZ <
-2. CD4 levels were measured in 38 children at ART
initiation. Median CD4 measurement was 11% [IQR 9-
15; n = 12] in children aged < 5 years and 151 cells/
mm
3 [IQR 38-188; n = 26] in children ≥ 5 years.
At therapy start, two children (2.3%) were ART-
experienced (M12 cohort). Two others had received pre-
vention of mother-to-child HIV infection prophylaxis,
one patient received short-course AZT together with
single-dose NVP (M12 cohort), and one patient received
single-dose NVP (M24 cohort). Seventy (81.4%) children
were started on AZT-3TC-NVP. A greater proportion of
children had received ARV pediatric formulation in the
M12 than in the M24 cohort (72.9% vs. 14.8%).
Characteristics at Survey
Mothers were the main caregivers for 50.8% of children
in the M12 cohort but only for 37.0% in the M24 cohort
(Table 2). Twenty-one percent of all children were
orphans.
Using the 4-day recall adherence indicator, all children
were classified as fully or moderately adherent to ART
(Table 2). The 30-day VAS classified 14% (M12) and
11% (M24) of children, respectively, as poorly adherent
to ART (< 95% score).
Gastrointestinal symptoms (43.0%) and peripheral
neuropathy (38.4%) were the most frequently reported
ARV-related toxicities. Morphological disorders were
diagnosed in 20.9% (18/86) of children, including
abdominal adipose tissue increase (15.1%, n = 13), lower
limb muscle loss (4.7%, n = 4), gluteal muscle loss
(3.5%, n = 3), breast adipose tissue increase (1.2%, n =
1), and facial muscle loss (1.2%, n = 1). Grade 1 or 2
neutropenia was the laboratory-related toxicity most fre-
quently observed (16.3%), and severe toxicity was found
in only one child (neutropenia of grade 3, M12).
Three children (11.1%) were in immunological failure
at the time of the study; all were aged ≥ 5 years and
received treatment for 2 years. In the M12 cohort, med-
ian CD4 percent gain was 11% [IQR 10-14; n = 10] in
children aged < 5 years, and CD4 count gain 206 cells/
mm
3 [IQR 98-348; n = 11] in those of ≥ 5 years. In the
M24 cohort, the CD4 percent gain was 11% [IQR 5-17;
n = 2] in children aged < 5 years, and CD4 count gain
132 cells/mm
3 [IQR 87-443; n = 15] in the elder group.
Plasma NNRTI Concentrations
Plasma concentrations of NNRTIs were measured in all
children: 81 receiving NVP-based and 5 EFV-based
Figure 1 Cohort profiles, Arua, Uganda, 2006.
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Page 3 of 9therapy. Median prescribed NVP dose per body surface
area was 150.3 mg/m
2 [IQR 124.1-184.9] and decreased
with increasing weight (Figure 2a). Subtherapeutic
NNRTI plasma levels were detected in 32.2% (19/59)
and 22.2% (6/27) of children at M12 and M24, respec-
tively (Table 2). Only children weighing < 30 kg were
found to be underdosed for NVP (37.0% of those who
were prescribed 100 mg, 18.8% of those on 200 mg, and
none of those on 25 mg of NVP twice daily; Figure 2b).
Those weighing 20-30 kg were more frequently under-
dosed for NVP than other children (51.9% compared to
21.3% for children of < 10 kg; P = 0.005). Furthermore,
16.9% (10/59) of M12 and 7.4% (2/27) of M24 children
had high plasma concentrations of NNRTIs (NVP or
EFV).
Virological Response and Drug Resistance
HIV RNA suppression (< 400 copies/mL) was observed
in 59.3% (35/59) of M12 and 33.3% (9/27) of M24
children (Table 3). Treatment adherence was not asso-
ciated with either viral suppression (overall Fisher’s
exact P = 0.42 for VAS and 1.00 for 4-day recall) or pre-
sence of low NNRTI plasma concentrations (P =0 . 3 5 ) .
Similarly, no association was observed between weight
and viral suppression (P = 0.17), and, among children
with detectable HIV RNA, weight was not correlated
with viral load measurements (overall Spearman’s corre-
lation coefficient 0.07, and 0.05 for M12 only).
Genotypic resistance testing was successful in all 34
specimens with viral load ≥ 1,000 copies/mL (Table 3).
HIV-1 subtypes were A1 (n = 7), C (n = 1), and D (n =
4), and for 22 children the subtype was not specified.
Wild-type viruses were found in 4 patients (3 at M12
and 1 at M24). The most prevalent mutations were
M184V (nucleoside reverse transcriptase inhibitors
[NRTIs]) and Y181C (NNRTIs). Twenty-nine (85.3%)
children had at least 1 major mutation conferring drug
resistance to both NRTIs and NNRTIs. Prevalence of
Table 1 Sociodemographic and clinico-immunological characteristics at ART initiation by cohort, Arua, Uganda, 2006
Patient characteristics M12 cohort M24 cohort
Eligible
(N = 70)
Surveyed
(N = 59)
Eligible
(N = 32)
Surveyed
(N = 27)
Demographic factors
Girls (%) 32 (45) 28 (47.5) 14 (44) 11 (40.7)
Median age, years [IQR] 5.4 [3.2 -8.2] 5.6 [3.2-8.3] 5.5 [4.2-7.7] 5.1 [4.2-7.5]
Age group (%)
12-35 months 13 (18.6) 12 (20.3) 6 (18.8) 5 (18.5)
36-59 months 19 (27.1) 14 (23.7) 6 (18.8) 6 (22.2)
5-14 years 38 (54.3) 33 (55.9) 20 (62.4) 16 (59.3)
Treatment history
ARV naïve (%) 67 (95.7) 56 (94.9) 31 (96.9) 26 (96.3)
Median follow-up without ARVs, months [IQR] 5.9 [3.5-11.1] 6.9 [4.2-13.3] 6.3 [1.7-12.0] 6.4 [1.7-12.3]
Clinical factors
Clinical stage (%) n = 68 n = 58 n = 32 n = 27
Stage 1/2 16 (23.6) 13 (25.9) 7 (21.9) 5 (18.5)
Stage 3 44 (63.2) 36 (62.1) 18 (56.2) 15 (55.6)
Stage 4 9 (13.2) 7 (12.0) 7 (21.9) 7 (25.9)
Weight-for-height z-score n = 62 n = 52 n = 29 n = 25
Median [IQR] -1.1
[-2.0 to -0.5]
-1.2
[-2.1 to -0.6]
-0.8
[-1.6 to -0.1]
-0.8
[-1.8 to -0.3]
< -2 score (%) 17 (27.4) 15 (28.8) 3 (10.3) 3 (12.0)
ART regimen (%)
AZT 3TC NVP 54 (77.1) 49 (83.1) 25 (78.1) 21 (77.8)
d4T 3TC NVP 16 (22.9) 10 (17.0) 7 (21.9) 6 (22.2)
CD4 testing, median [IQR]
CD4 cell count
a n = 14 n = 11 n = 17 n = 15
190 [106-302] 200 [166-302] 70 [22-149] 70 [20-152]
CD4%
b n=1 2 n=1 0 n=2 n=2
10 [8-14] 11 [8-14] 14 [10-17] 13 [10-17]
Note: ART, antiretroviral therapy; 3TC, lamivudine; d4T, stavudine; NVP, nevirapine; AZT, zidovudine.
a Number of children aged ≥ 5 years in M12 = 38 and in M24 = 20.
b Number of children aged < 5 years in M12 = 32 and in M24 = 12.
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children who had 400-999 HIV RNA copies/mL was
25% (13/52) at M12 and 62% (16/26) at M24. Twelve
( M 1 2 )a n d6( M 2 4 )c h i l d r e nh a dv i r u s e sr e s i s t a n tt o
both 3TC and NNRTIs (EFV and NVP). Eight
specimens from the M24 cohort had K65R, T69A,
V751, K103N, F116Y, Q151M, V179S, Y181C, and
M184V mutations, conferring resistance to all NRTIs
and to EFV and NVP.
Discussion
In these two pediatric cohorts of children followed in
rural Uganda, we found retention rates of 86% and sus-
tained immunological responses 1 and 2 years after
ART start. Nevertheless, virological responses were sub-
optimal, as only 59% of M12 and 33% of M24 children
achieved HIV viral suppression, and resistant viral
strains were found in 25% and 62% of children,
respectively.
As in other sub-Saharan African cohorts [25-28], all
children followed in our program were enrolled and
started therapy after the first year of life, median age at
inclusion being 5 years old. Given that young, untreated
children are at high risk of rapid disease progression
and death before the age of 2 years [3,29-32], the overall
impact of HIV/AIDS programs in children living in
these settings is likely to be suboptimal. Thus, delay in
diagnosis of pediatric HIV infection and lack of avail-
ability of integrated HIV care and treatment in maternal
and child health services at the time of the survey were
likely to be partly responsible for the late start of ther-
apy in our site.
Furthermore, as in other pediatric cohorts in resource-
limited settings [26,27,33,34], children in our program
started therapy at advanced clinico-immunological stage
and the majority of deaths and LFU occurred early in
treatment. Delayed diagnosis of HIV infection and fail-
ure to diagnose and treat concurrent life-threatening
infections such as tuberculosis, pneumonia, or sepsis
[35] might be responsible for the early losses reported.
Starting ART before 12 weeks of life has recently been
associated with a 76% reduction in child mortality com-
pared to deferred therapy until immunological or clini-
cal progression is diagnosed [36]. Therefore, some of
the early losses in our cohort could have been prevented
if ART was started earlier. Despite this, we observed
overall high and sustained survival and retention rates
in children treated with ART up to 2 years after therapy
start. These findings are consistent with reports from
other programs from resource-limited settings
[10,25,37].
Although direct comparison of immunological
responses across studies is not possible because of its
high dependence on patient age [38], we observed sig-
nificant CD4 T-cell responses to ART independent of
the virological status of the patient, and, as previously
reported [27,28,38,39], greater increases were seen in
the first than in the second year of therapy among chil-
dren aged ≥5 years (gains of 206 vs. 132 cells/mm
3).
Table 2 Patient characteristics at survey evaluation by
cohort, Arua, Uganda, 2006
Children aged < 15 years M12 cohort
(N = 59)
M24 cohort
(N = 27)
Type of caregiver (%)
Mother 30 (50.8) 10 (37.0)
Father 6 (10.2) 3 (11.1)
Another relative 21 (35.6) 13 (48.2)
Other 2 (3.4) 1 (3.7)
Father receiving ART (%) 17 (28.8) 4 (14.8)
Mother receiving ART (%) 29 (49.2) 11 (40.7)
Both parents died (%) 12 (20.3) 6 (22.2)
Clinico-immunological characteristics
Cumulative clinical stage (%)
Stage 1/2 13 (22.0) 3 (11.1)
Stage 3 26 (44.1) 10 (37.0)
Stage 4 20 (33.9) 14 (51.9)
Weight gain, kg, median [IQR] 4 [3-5] 5 [4-7]
Weight-for-height z-score (%) n = 51 n = 22
< -2 z-score 2 (3.9) 2 (9.1)
Reported ARV-related toxicity
Asthenia 8 (13.6) 2 (7.4)
Gastrointestinal symptoms 25 (42.4) 12 (44.4)
Neurological disorders 23 (39.7) 10 (37.0)
Morphological disorders 13 (22.0) 5 (18.5)
Adherence to ART
4-day recall (%)
Good (100%) 49 (83) 23 (85)
Moderate (95-99%) 10 (17) 4 (15)
Poor (< 95%) 0 (0) 0 (0)
30-day VAS
a (%)
Good (100%) 28 (48) 19 (70)
Moderate (95-99%) 22 (38) 5 (19)
Poor (< 95%) 8 (14) 3 (11)
Median CD4 testing [IQR]
CD4 cell count, cell/μL n=3 3 n=1 6
504 [399-715] 210 [124-458]
CD4% n = 26 n = 11
25 [21-29] 20 [16-27]
Plasma EFV concentrations (%) n = 5
Low (< 1,000 ng/mL) 1 (20.0) -
High (> 4,000 ng/mL) 1 (20.0)
Plasma NVP concentrations (%) n = 54 n = 27
Low (< 4,000 ng/mL) 18 (33.3) 6 (22.2)
High (> 8,000 ng/mL) 9 (16.7) 2 (7.4)
Note: ARV, antiretroviral; ART, antiretroviral therapy; EFV, efavirenz; IQR,
interquartile range; NVP, nevirapine; VAS, visual analogue scale.
aMissing information for one patient in the M12 cohort.
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when interpreting these findings. The small numbers of
patients did not allow investigating risk factors for virolo-
gical failure. Estimates reported in other studies range
from 49% in Abidjan, Côte d’Ivoire, to 80% in 63 children
exposed to single-dose NVP in Durban, South Africa, at
one year of therapy [9,27,40-42]. In the urban studies in
Côte d’Ivoire and South Africa, 49% virological suppres-
sion was reported at 2 years of ART [9,27]. Large differ-
ences in virological response rates have been observed
between clinical studies among children, and the majority
showed lower rates than in adults [38]. Possible explana-
tions for such discrepancies could be differences in patient
characteristics at ART initiation, regimens used, pediatric
dose formulations, drug pharmacokinetics, and/or inade-
quate compliance to treatment.
As mentioned before, most children in our cohort
started treatment at an advanced stage of disease. Pre-
sence of high HIV RNA at therapy start has been asso-
ciated with slower decay rates of plasma viral levels and
longer time to reach undetectable viral levels [42-45].
Increased risk of virological failure has also been
reported in children with CD4 < 5% [40]. Our patients
received NNRTI-based therapy, and most were given
NVP. Higher rates of virological success have been
shown in young patients treated with protease inhibitors
than in those using NNRTI regimens in some [9] but
not all studies [27,46]. Furthermore, virological response
has also been shown to vary in clinical studies using the
same medication [38].
Ensuring adequate administration of ART to children
is difficult and requires continuous dose adjustment in
Figure 2 Association between weight and (2a) daily NVP, and (2b) NVP plasma concentration, Arua, Uganda, 2006. 2a) Prescribed daily
NVP per body surface area (mg/m
2) by children’s weight (kg) 2b) NVP plasma concentration (ng/mL) by children’s weight (kg).
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to growth. In our cohorts, 1 in 4 children had subthera-
peutic NVP plasma concentrations, especially children
in the 20-30 kg weight range, highlighting the need for
close monitoring of treatment, clear and simplified
treatment guidelines, and availability of appropriate
pediatric dose formulations.
Ensuring and maintaining good treatment adherence
in children is also challenging, especially in resource-
limited settings, since many children are orphans or live
in difficult social situations: 1 in 5 patients were orphans
in our study, and 43% had a caregiver other than a par-
ent. Furthermore, palatable syrups or appropriate pedia-
tric tablet formulations are expensive and not broadly
available. In our study, 13% of children were identified
as poorly adherent to ART, but this is likely to be
underestimated since it was based on parental or care-
giver reports. Four children with virological failure had
wild-type virus and had therefore not been taking any
treatment for some time. Furthermore, the prevalence of
resistance mutations was relatively high but similar to
those reported by a previous study in Côte d’Ivoire [26].
A recent review of studies investigating ART adherence
in children treated in low- and middle-income countries
identified difficult familial situations and low socioeco-
nomic status, absence of parental and/or child HIV sta-
tus disclosure, complicated regimens, and drug-related
adverse events as barriers to treatment adherence
[47,48]. Age-adapted therapeutic education of children
and extensive discussions and support to parents/care-
givers need to be encouraged to improve ART uptake in
this vulnerable group.
As reported by others [38,49], we did not observe
severe adverse drug reactions at the time of the survey,
apart from one patient with severe neutropenia. How-
ever, 3 of 7 children reported gastrointestinal symptoms,
which might interfere with drug absorption and affect
treatment adherence [50]. Peripheral neuropathy and
morphological disorders were not uncommon (38% and
21% of children, respectively). One longitudinal and one
cross-sectional study also reported relatively high rates
of lipodystrophy in children treated with d4T or pro-
tease inhibitors (29% and 33% of children, respectively),
especially in those who started therapy at an advanced
stage of disease [51,52]. This syndrome is frequently
associated with metabolic abnormalities such as hyperin-
sulinemia and dyslipidemia. However, its causal link to
ART is to be established, and its long-term conse-
quences for the treatment of children are unknown [52].
Conclusions
Important challenges need to be tackled to improve HIV
pediatric care in resource-limited settings. These include
increasing early HIV diagnosis through programs for the
prevention of mother-to-childH I Vt r a n s m i s s i o n ,t r a i n -
ing in pediatric clinical management and adherence
counseling, and development of palatable and simplified
pediatric drug formulations.
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